Thursday, February 19, 2026 2/19/2026

Targeting SEC61 complex to overcome resistance to immunotherapy in GBM

Award Number: R01CA290737
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2029

Group Awards By:

View Award Description

Targeting SEC61 complex to overcome resistance to immunotherapy in GBM - Glioblastoma (GBM) is an incurable brain tumor with a median overall survival of less than 15 months. The recent success of immunotherapy in extracranial malignancies has translated into trials for GBM. Despite its promise, immunotherapy's clinical efficacy has yet to be shown for GBM. The resistance to immunotherapy in GBM is multifactorial. To uncover the targets and pathways contributing to resistance in GBM, we designed and performed an unbiased, genome-wide CRIPR-Cas9 knockout screen screening in a glioma cell line under a cytotoxic T-cell mediated selection pressure. This screen identified SEC61subunit gamma (SEC61G) as a gene involved in immunotherapeutic resistance in GBM. SEC61G is a component of the SEC61 translocon complex in the endoplasmic reticulum. Our data shows that SEC61G is highly expressed in GBM, with genomic amplification seen in up to 30-40% of GBM patients. Knocking out SEC61G sensitized glioma cells to T cell- mediated therapy in vitro. Proteomic analysis of SEC61G knockout cells revealed an interplay of SEC61G expression with the activation of the MAPK pathway in glioma cells. The proposed pre-clinical investigation aims to understand the role SEC61G in immunotherapeutic resistance in GBM and to evaluate SEC61G as a therapeutic target in combination with immunotherapy. We hypothesize that SEC61G confers resistance to T cell-mediated immunotherapy in GBM and that targeting SEC61G can significantly enhance the response of GBM to immunotherapy. This hypothesis will be tested in three Specific Aims. SA1 will investigate how SEC61G overexpression interconnects with the MAPK pathway and contributes to the T cell-mediated therapeutic resistance in glioma cells. SA2 will determine the contribution of SEC61G to the immunosuppressive tumor microenvironment impeding the responses of T cells in GBM. SA3 will investigate SEC61G treatment regimens in combination with T-cell mediated therapies using murine and human models of GBM. Upon completing these studies, we will understand the mechanisms underlying SEC61G-mediated immunotherapeutic resistance, characterize SEC61G as a therapeutic target, and yield translational results for the treatment of GBM and potentially other solid tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $519,870 )
2026	2026	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Treatment Research	000	2	2/10/2026	NON-COMPETING CONTINUATION	$519,870
														Subtotal = $519,870

Issue Date FY: 2025 ( Subtotal = $577,634 )
2025	2025	NORTHWESTERN UNIVERSITY	633 CLARK ST	EVANSTON	IL	60208	COOK	USA	Cancer Treatment Research	000	1	12/26/2024	NEW	$577,634
														Subtotal = $577,634

Grand Total All Awards = $1,097,504

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting SEC61 complex to overcome resistance to immunotherapy in GBM

Award Number: R01CA290737

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer